PT  - JOURNAL ARTICLE
AU  - J.Y. Jeon
AU  - I. Kovanlikaya
AU  - J.A. Boockvar
AU  - X. Mao
AU  - B. Shin
AU  - J. K. Burkhardt
AU  - K. Kesavabhotla
AU  - P. Christos
AU  - H. Riina
AU  - D.C. Shungu
AU  - A.J. Tsiouris
TI  - Metabolic Response of Glioblastoma to Superselective Intra-Arterial Cerebral Infusion of Bevacizumab: A Proton MR Spectroscopic Imaging Study
AID  - 10.3174/ajnr.A3091
DP  - 2012 Dec 01
TA  - American Journal of Neuroradiology
PG  - 2095--2102
VI  - 33
IP  - 11
4099  - http://www.ajnr.org/content/33/11/2095.short
4100  - http://www.ajnr.org/content/33/11/2095.full
SO  - Am. J. Neuroradiol.2012 Dec 01; 33
AB  - BACKGROUND AND PURPOSE: SIACI of bevacizumab has emerged as a promising novel therapy in the treatment of recurrent GB. This study assessed the potential of 1H-MRS as an adjunctive technique in detecting metabolic changes reflective of antiproliferative effects of targeted infusion of bevacizumab in the treatment of GB. MATERIALS AND METHODS: Eighteen patients enrolled in a phase I/II study of SIACI of bevacizumab for treatment of recurrent GB were included. Concurrent MR imaging and 1H-MRS scans were performed before and after treatment. Five distinct morphologic ROIs were evaluated for structural and metabolic changes on MR imaging and 1H-MRS, which included enhancing, nonenhancing T2 hyperintense signal abnormality, and multiple control regions. Pre- and post-SIACI of bevacizumab peak areas for NAA, tCho, tCr, as well as tCho/tCr and tCho/NAA ratios, were derived for all 5 ROIs and compared using the Wilcoxon signed-rank test. RESULTS: A significant median decrease of 25.99% (range −55.76 to 123.94; P = .006) in tCho/NAA was found post-SIACI of bevacizumab relative to pretreatment values in regions of enhancing disease. A trend-level significant median decrease of 6.45% (range −23.71 to 37.67; P = .06) was noted in tCho/NAA posttreatment in regions of nonenhancing T2-hyperintense signal abnormality. CONCLUSIONS: The results of this 1H-MRS analysis suggest that GB treatment with SIACI of bevacizumab may be associated with a direct antiproliferative effect, as demonstrated by significant reductions of tCho/NAA after the intervention. GBglioblastomaIAintra-arterialIDLInteractive Data LanguageLaclactatePFSprogression-free survivalRANOresponse assessment in neuro-oncologySIACIsuperselective intra-arterial cerebral infusiontChototal cholinetCrtotal creatine